Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.68 | Change: +$0.60 | %Change: +11.81%
Volume: 135,760 | Day High/Low: 5.95/5.08 | 52 Week High/Low: 10.36/2.50
View modes: 
1 star

RE:Presentation

What after hours trade?  Link? Level 2 above shows the last trade at 3:59 on a couple of hundred shares./  rate and reply
4 stars

Presentation

Incredible updates for both P2 and WF10. Both blockbusters. No PR? Interesting after hours trade. We'll see what happens when the US opens tomorrow. Huge money at stake here... I expect more...read more
5 stars

RE:Are we at $6.50 yet

Momma Mia ....about time  rate and reply
1 star

Are we at $6.50 yet

darn.....soon I guess  rate and reply
5 stars

RE:Big Move with US Market Closed

Finally the market recgonizes (gives credit) for the cash position and the failed allergy testing protocol. Wonder how/if the US market close is impacting today's "spike"?  Or should we wait for a...read more
5 stars

RE:Big Move with US Market Closed

We are still just trading above our shareholder equity which is 95 % hard cash. Consider that CPH which is  very good proxy for Nuvo trades at 4.5 times its shareholder equity ( current assets less...read more
5 stars

Big Move with US Market Closed

$5.90 trades up $0.82 (+16%) on 80,800 shares traded and the US market closed for a holiday today. Perhaps we'll see some follow-through buying tomorrow. Clearly there are no big sell orders on Level...read more
0 stars

RE:RE:RE:RE:RE:Massive Failure to Communicate

Having Mgmt promote has always been an issue. However, on the few occasions they have spoken to media - you wished they didn't bother. Interesting in one slide they show "we know how to partner" and a...read more
5 stars

RE:RE:bullish breakout over 200 dma for nuvo.....

Yes there is a clear and decisive breakout in the share price and there is one heck of a big price gap fill coming - from $5.65 to $8.61 I like stocks that have positive technical patterns and are...read more
0 stars

RE:RE:RE:RE:Massive Failure to Communicate

Humm, I wish more than I which for an announcement...  rate and reply
5 stars

RE:bullish breakout over 200 dma for nuvo.....

i dont know how to insert charts imto my posts but nuvo is breaking out of a 5 month channel, bullish setup....glta  rate and reply
5 stars

New Presentation Very Revealing

First, the secondary efffects of WF10. Although the trials targetted SARs ( seasonal allergies such as grasses ) and failed due to a very weak allergy season ( the subjects were not allergy...read more
5 stars

RE:RE:RE:Massive Failure to Communicate

Yes, it is a new slide and is very revealing of wf10 efficacity.  Now I which management would put out a news annancement about this very significant information as well.  rate and reply
5 stars

RE:RE:Massive Failure to Communicate

Not sure slide 16 has been shown before, showing the longer term affect of the 2014 perennial allergy patients showing definite separation of placebo from WF10!  rate and reply
5 stars

RE:Massive Failure to Communicate

New presentation on their website, the graph on page 8 keeps on trending higher.  rate and reply
0 stars

Massive Failure to Communicate

What we have here is a massive failure by management to communicate the merits of this story to investors. Still trading below cash value with product sales of $25 million per year that are being...read more
0 stars

RE:Voltaren Gel sales growth in US

The reason for sustained growth after the first year was name branding. So shall it be with the new kid on the block, who looks to be ready to take over the street.  rate and reply
0 stars

RE:Voltaren Gel sales growth in US

Voltaren Sales in Europe were $318 million in 2011 and $632 million for Novartis outside US. Lots of room for competition.  rate and reply
0 stars

RE:Synera product

According to the notes for the Q1 2015 results Nuvo received $41,000 for the bulk sale of HTL (the active ingredient) used in the manufacture of the Patch. The ingredient is shipped to a CMO that...read more
0 stars

Synera product

Does anyone know what happened to this product. This is from the MDA The quarter ended September 30, 2013 included a US$4.5 million upfront payment from Galen for the exclusive rights to sell and...read more